Cargando…

Re-Irradiation for Head and Neck Cancer: Cumulative Dose to Organs at Risk and Late Side Effects

SIMPLE SUMMARY: Local recurrences of head and neck cancer are unfortunately common and can be difficult to treat. The treatment is challenging, partly due to the location, with several important organs in the head and neck area, but also because recurrence often occurs in an area already treated wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Embring, Anna, Onjukka, Eva, Mercke, Claes, Lax, Ingmar, Berglund, Anders, Bornedal, Sara, Wennberg, Berit, Dalqvist, Emmy, Friesland, Signe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8269009/
https://www.ncbi.nlm.nih.gov/pubmed/34202135
http://dx.doi.org/10.3390/cancers13133173
_version_ 1783720480697483264
author Embring, Anna
Onjukka, Eva
Mercke, Claes
Lax, Ingmar
Berglund, Anders
Bornedal, Sara
Wennberg, Berit
Dalqvist, Emmy
Friesland, Signe
author_facet Embring, Anna
Onjukka, Eva
Mercke, Claes
Lax, Ingmar
Berglund, Anders
Bornedal, Sara
Wennberg, Berit
Dalqvist, Emmy
Friesland, Signe
author_sort Embring, Anna
collection PubMed
description SIMPLE SUMMARY: Local recurrences of head and neck cancer are unfortunately common and can be difficult to treat. The treatment is challenging, partly due to the location, with several important organs in the head and neck area, but also because recurrence often occurs in an area already treated with radiotherapy. It has been shown that repeat radiotherapy, re-irradiation, can offer long-lasting tumor control and sometimes even cure in selected patients. However, there is a risk of normal tissue close to the tumor being damaged by high cumulative doses of radiotherapy. In this study, we aim to establish levels of cumulative dose to specific organs that could be considered reasonably safe to deliver at re-irradiation without causing high rates of severe side effects. Increased knowledge in dose–response relationships in re-irradiation for head and neck cancer will facilitate a tailored treatment for the individual patient. ABSTRACT: Re-irradiation in head and neck cancer is challenging, and cumulative dose constraints and dose/volume data are scarce. In this study, we present dose/volume data for patients re-irradiated for head and neck cancer and explore the correlations of cumulative dose to organs at risk and severe side effects. We analyzed 54 patients re-irradiated for head and neck cancer between 2011 and 2017. Organs at risk were delineated and dose/volume data were collected from cumulative treatment plans of all included patients. Receiver–operator characteristics (ROC) analysis assessed the association between dose/volume parameters and the risk of toxicity. The ROC-curve for a logistic model of carotid blowout vs. maximum doses to the carotid arteries showed AUC = 0.92 (95% CI 0.83 to 1.00) and a cut-off value of 119 Gy (sensitivity 1.00/specificity 0.89). The near-maximum dose to bones showed an association with the risk of osteoradionecrosis: AUC = 0.74 (95% CI 0.52 to 0.95) and a cut-off value of 119 Gy (sensitivity 1.00/specificity 0.52). Our analysis showed an association between cumulative dose to organs at risk and the risk of developing osteoradionecrosis and carotid blowout, and our results support the existing dose constraint for the carotid arteries of 120 Gy. The confirmation of these dose–response relationships will contribute to further improvements of re-irradiation strategies.
format Online
Article
Text
id pubmed-8269009
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-82690092021-07-10 Re-Irradiation for Head and Neck Cancer: Cumulative Dose to Organs at Risk and Late Side Effects Embring, Anna Onjukka, Eva Mercke, Claes Lax, Ingmar Berglund, Anders Bornedal, Sara Wennberg, Berit Dalqvist, Emmy Friesland, Signe Cancers (Basel) Article SIMPLE SUMMARY: Local recurrences of head and neck cancer are unfortunately common and can be difficult to treat. The treatment is challenging, partly due to the location, with several important organs in the head and neck area, but also because recurrence often occurs in an area already treated with radiotherapy. It has been shown that repeat radiotherapy, re-irradiation, can offer long-lasting tumor control and sometimes even cure in selected patients. However, there is a risk of normal tissue close to the tumor being damaged by high cumulative doses of radiotherapy. In this study, we aim to establish levels of cumulative dose to specific organs that could be considered reasonably safe to deliver at re-irradiation without causing high rates of severe side effects. Increased knowledge in dose–response relationships in re-irradiation for head and neck cancer will facilitate a tailored treatment for the individual patient. ABSTRACT: Re-irradiation in head and neck cancer is challenging, and cumulative dose constraints and dose/volume data are scarce. In this study, we present dose/volume data for patients re-irradiated for head and neck cancer and explore the correlations of cumulative dose to organs at risk and severe side effects. We analyzed 54 patients re-irradiated for head and neck cancer between 2011 and 2017. Organs at risk were delineated and dose/volume data were collected from cumulative treatment plans of all included patients. Receiver–operator characteristics (ROC) analysis assessed the association between dose/volume parameters and the risk of toxicity. The ROC-curve for a logistic model of carotid blowout vs. maximum doses to the carotid arteries showed AUC = 0.92 (95% CI 0.83 to 1.00) and a cut-off value of 119 Gy (sensitivity 1.00/specificity 0.89). The near-maximum dose to bones showed an association with the risk of osteoradionecrosis: AUC = 0.74 (95% CI 0.52 to 0.95) and a cut-off value of 119 Gy (sensitivity 1.00/specificity 0.52). Our analysis showed an association between cumulative dose to organs at risk and the risk of developing osteoradionecrosis and carotid blowout, and our results support the existing dose constraint for the carotid arteries of 120 Gy. The confirmation of these dose–response relationships will contribute to further improvements of re-irradiation strategies. MDPI 2021-06-25 /pmc/articles/PMC8269009/ /pubmed/34202135 http://dx.doi.org/10.3390/cancers13133173 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Embring, Anna
Onjukka, Eva
Mercke, Claes
Lax, Ingmar
Berglund, Anders
Bornedal, Sara
Wennberg, Berit
Dalqvist, Emmy
Friesland, Signe
Re-Irradiation for Head and Neck Cancer: Cumulative Dose to Organs at Risk and Late Side Effects
title Re-Irradiation for Head and Neck Cancer: Cumulative Dose to Organs at Risk and Late Side Effects
title_full Re-Irradiation for Head and Neck Cancer: Cumulative Dose to Organs at Risk and Late Side Effects
title_fullStr Re-Irradiation for Head and Neck Cancer: Cumulative Dose to Organs at Risk and Late Side Effects
title_full_unstemmed Re-Irradiation for Head and Neck Cancer: Cumulative Dose to Organs at Risk and Late Side Effects
title_short Re-Irradiation for Head and Neck Cancer: Cumulative Dose to Organs at Risk and Late Side Effects
title_sort re-irradiation for head and neck cancer: cumulative dose to organs at risk and late side effects
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8269009/
https://www.ncbi.nlm.nih.gov/pubmed/34202135
http://dx.doi.org/10.3390/cancers13133173
work_keys_str_mv AT embringanna reirradiationforheadandneckcancercumulativedosetoorgansatriskandlatesideeffects
AT onjukkaeva reirradiationforheadandneckcancercumulativedosetoorgansatriskandlatesideeffects
AT merckeclaes reirradiationforheadandneckcancercumulativedosetoorgansatriskandlatesideeffects
AT laxingmar reirradiationforheadandneckcancercumulativedosetoorgansatriskandlatesideeffects
AT berglundanders reirradiationforheadandneckcancercumulativedosetoorgansatriskandlatesideeffects
AT bornedalsara reirradiationforheadandneckcancercumulativedosetoorgansatriskandlatesideeffects
AT wennbergberit reirradiationforheadandneckcancercumulativedosetoorgansatriskandlatesideeffects
AT dalqvistemmy reirradiationforheadandneckcancercumulativedosetoorgansatriskandlatesideeffects
AT frieslandsigne reirradiationforheadandneckcancercumulativedosetoorgansatriskandlatesideeffects